Abstract
Gastric epithelial neoplasms of the fundic-gland mucosa lineage (GEN-FGMLs) are rare gastric tumors including oxyntic gland adenoma (OGA), gastric adenocarcinoma of the fundic-gland type (GA-FG), and gastric adenocarcinoma of the fundic-gland mucosa type (GA-FGM). Due to their low cellular atypia and similarity to normal gastric tissue, these tumors are frequently misdiagnosed. This study analyzed 37 cases to identify key clinicopathological features and diagnostic thresholds. Findings indicate that tumor size (>4.5 mm) and the Ki67 proliferation index (>2.5%) are critical for distinguishing between benign OGAs and low-grade adenocarcinomas (GA-FG/GA-FGM).
Introduction
In gastric oncology, most malignancies are characterized by high-grade atypia—cells that appear disorganized and clearly abnormal. However, Gastric Epithelial Neoplasms of Fundic-Gland Mucosa Lineage (GEN-FGMLs) represent a "low atypia" category of tumors that mimic the normal fundic glands of the stomach lining. This group includes Oxyntic Gland Adenomas (OGA), Gastric Adenocarcinoma of the Fundic-Gland type (GA-FG), and the rare Fundic-Gland Mucosa type (GA-FGM). The lack of global consensus on classification and their benign appearance under standard microscopy often leads to a "diagnostic trap," resulting in either overtreatment or overlooked malignancy.
Methods
Researchers conducted a retrospective analysis of 37 patients diagnosed with GEN-FGMLs at Fujian Provincial Hospital between 2019 and 2023. The study utilized:
- Histopathology: Review of H&E-stained slides to observe tissue architecture and cellular morphology.
- Immunohistochemistry (IHC): Analysis of markers including MUC6 and pepsinogen-I (to confirm fundic gland origin) and Ki67 (to measure cell proliferation).
- Statistical Analysis: Receiver Operating Characteristic (ROC) curves were used to determine optimal diagnostic "cut-off" values for tumor size and Ki67 levels.
Key Clinicopathological Features
The study cohort consisted of 19 OGAs, 16 GA-FGs, and 2 GA-FGMs. The median age of patients was 60 years. Morphologically, these tumors demonstrated well-formed glands with pale, blue-grey columnar cells resembling normal fundic gland cells.
Diagnostic Thresholds
The analysis identified two primary markers for differentiating benign OGA from malignant GA-FG/GA-FGM:
- Tumor Size: Lesions larger than 4.5 mm were significantly more likely to be adenocarcinomas ($p < 0.0001$). Larger size also correlated with a higher risk of submucosal invasion.
- Ki67 Proliferation Index: While all GEN-FGMLs show low proliferation, a Ki67 index greater than 2.5% served as a strong indicator of adenocarcinoma ($p < 0.0001$).
Biomarker Profile
All cases showed diffuse positivity for MUC6 and pepsinogen-I, confirming their lineage. A notable morphological distinction was found at the surface: while OGAs and GA-FGs are typically covered by normal gastric pit epithelium, GA-FGMs are characterized by dysplastic pit epithelium.
Clinical Outcomes and Prognosis
Despite their classification as adenocarcinomas, GA-FGs and GA-FGMs exhibited favorable biological behavior. During a mean follow-up period of 20.6 months, no cancer-related deaths occurred, and only one patient presented with lymph node metastasis. This suggests that while these tumors are technically malignant, they are relatively indolent.
Conclusion and Future Directions
GEN-FGMLs are a group of well-differentiated gastric tumors with low cellular atypia and favorable outcomes. Accurate diagnosis is critical to avoid overtreatment. Pathologists and endoscopists should utilize tumor size and the Ki67 proliferation index as key diagnostic aids. However, the rarity of these tumors results in small sample sizes, particularly for the GA-FGM subtype. Future multi-center studies are needed to validate the 4.5 mm and 2.5% Ki67 thresholds and explore the underlying molecular drivers, such as GNAS mutations, to better understand the progression from benign adenoma to invasive carcinoma.
Summary updated